Eliem Therapeutics Inc.

NASDAQ: ELYM · Real-Time Price · USD
5.11
-0.05 (-0.97%)
At close: Oct 02, 2024, 10:00 PM

Eliem Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost of Revenue
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Gross Profit
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Income
-108.64M -88.63M -24.57M -17.84M -19.84M -40.27M -44.71M -48.45M -55.44M -45.13M -46.28M -46.92M -41.92M -35.67M -40.08M -32.95M -25.85M
Interest Income
-2.69M -1.35M 2.69M 3.95M 3.95M 2.61M 1.26M 384.52K 383.41K 383K 383K n/a n/a n/a n/a n/a n/a
Pretax Income
-98.23M -79.15M -69.12M -64.19M -14.53M -35.12M -39.24M -44.95M -54.33M -45.24M -48.03M -47.96M -42.08M -47.48M -51.8M -44.44M -37.35M
Net Income
-98.23M -79.15M -69.12M -64.19M -14.53M -33.97M -36.3M -42.01M -52.28M -44.42M -48.99M -48.93M -42.16M -47.48M -51.8M -44.44M -37.35M
Selling & General & Admin
23.3M 19.52M 13.07M 9.7M 9.06M 24.86M 27.5M 29.86M 31.77M 18.92M 18.12M 17.02M 15M 12.35M 10.06M 6.98M 4.32M
Research & Development
33.37M 17.14M 11.35M 8.14M 10.78M 15.41M 17.21M 18.59M 23.67M 26.21M 28.17M 29.9M 26.92M 23.32M 20.86M 16.81M 12.38M
Other Expenses
51.97M 51.97M 153K n/a n/a n/a n/a n/a n/a 85K 145K 165K 165K 80K 20K n/a n/a
Operating Expenses
108.64M 88.63M 24.57M 17.84M 19.84M 40.27M 44.71M 48.45M 55.44M 45.13M 46.28M 46.92M 41.92M 35.67M 30.92M 23.79M 16.7M
Interest Expense
-1.15M -1.15M 1.15M 1.15M 1.15M 1.15M n/a n/a 1.64M 1.87M 1.87M 1.87M 229K n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
85.63M 88.63M 24.57M 17.84M 19.84M 40.27M 44.71M 48.45M 55.44M 45.13M 46.28M 46.92M 41.92M 35.67M 30.92M 23.79M 16.7M
Income Tax Expense
3.01M 3.01M -3.06K -7.83K -7.83K -1.16M -2.94M -2.94M -2.04M -825K 967K 967K 72K n/a -9.16M -9.16M -9.16M
Shares Outstanding (Basic)
67.46M 48.16M 67.01M 30.35M 27.64M 27.7M 27.07M 26.84M 26.49M 26.37M 26.34M 26.3M 26.24M 26.23M 15.59M 23.46M 11.66M
Shares Outstanding (Diluted)
67.46M 48.16M 67.01M 30.35M 27.64M 27.7M 27.07M 26.84M 26.49M 26.37M 26.34M 26.3M 26.24M 26.23M 15.59M 23.46M 11.66M
EPS (Basic)
-1.78 -1.53 -2.13 -2.15 -0.53 -1.27 -1.37 -1.59 -1.99 -1.7 -1.87 -2.12 -1.9 -2.99 -3.86 -3.43 -3.2
EPS (Diluted)
-1.78 -1.53 -2.13 -2.15 -0.53 -1.27 -1.37 -1.59 -1.99 -1.7 -1.87 -2.12 -1.9 -2.99 -3.86 -3.43 -3.2
EBITDA
-108.99M -88.98M -76.23M -69.5M -19.84M -40.27M -41.31M -45.05M -52.04M -41.73M -46.28M -46.92M -41.92M -35.67M -30.91M -21.99M -13.76M
EBIT
-3.6M -6.61M -76.23M -69.5M -19.84M -40.27M -44.71M -48.45M -55.44M -45.13M -46.28M -46.92M -41.92M -35.67M -30.92M -23.79M -16.7M
Depreciation & Amortization
-6.06M -3.06M 6.06M 10.84M 16.82M 21.47M 27.96M 31.93M 39.65M 45.13M 46.28M 46.92M 41.92M 35.67M 30.92M 23.79M 16.7M